Phase 1Completed
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)
- Sponsor
- Tobira Therapeutics, Inc. (Industry)
- Enrollment
- 48 enrolled
- Conditions
- Healthy
- Interventions
- Cenicriviroc; Omeprazole; Famotidine
- Ages
- adults
- Registry
- NCT02684799
Full record on ClinicalTrials.gov
From the registry
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Primary outcomes
- Pharmacokinetic Assessment of CVC, as measured by maximum plasma concentration (Cmax)
- Pharmacokinetic Assessment of CVC, as measured by minimum plasma concentration (Cmin)
- Pharmacokinetic Assessment of CVC, as measured by area under the plasma concentration-time curve (AUC)
History
Last registry update
Primary completion
Registered
Started